A Study of the Cardiotoxicity of Combination with Chemotherapy and Targeted Therapy for Breast Cancer
Objective To evaluate the cardiotoxicity of chemotherapy combined with targeted therapy for HER2 positive breast cancer.Metholds Patients were devided into:chemotherapy group(C group;51 cases),chemotherapy plus trastuzumab group(C+H group;62 cases)and chemotherapy plus trastuzumab and pertuzumab group(C+H+P group;47 cases).The changes of heart rate,left ventricular ejection fraction(LVEF)and creatine kinase-MB(CK-MB)at baseline,3,6,9,12 and 24 month after treatment were analyzed,and the Incidence rate of cardiotoxicity was also calculated.Results The LVEF level in C group significantly de-creased at 3 month,6 mouth and 9 mouth(all P＜0.05),the same significant differences were also detected in C+H group and C+H+P group at 3 month,6 month,9 month and 12 month(all P＜0.01).The comparison in groups:For C group,the LVEF level of C+H group and C+H+P group at 3 month and 6 month significantly decreased(all P＜0.01);there were no significant differences in heart rate and CK-MB.The cardiotoxicity was found in 5 patients of C group,20 patients of C+H group and 14 patients of C+H+P group,and there was statistical difference between groups(P＜0.05),and there was no statistical difference between C+H group and C+H+P group(P>0.05).Conclusion Differences of cardiotoxicity between chemotherapy combined with single or double tar-geted therapy were not detected,and most of them can recoverable.The LVEF level may be used as an effective method to predict cardiotoxicity of targeted therapy.
Her2 positive breast cancertrastuzumabpertuzumabcardiotoxicity
万方数据
维普
